Melanoma develops from melanocytes, the pigment-producing cells that help protect tissues from ultraviolet radiation. Although most melanomas begin in the skin, the disease can also arise in mucosal tissues lining structures such as the ears, nose, lungs, mouth and digestive tract. Once melanoma spreads to distant organs or becomes resistant to immune checkpoint inhibitors and other treatments, therapeutic options can be limited. The new trial is therefore focused on a group of patients with particularly aggressive disease and a high unmet medical need.

DOC1021 is built around dendritic cells, specialized antigen-presenting cells that coordinate the immune response. Dendritic cells collect molecular information from foreign organisms or abnormal cells and display fragments of that material to T cells, helping determine what the immune system should attack. In the investigational treatment, a patient’s dendritic cells are combined with messenger RNA, or mRNA, and proteins derived from a biopsy of the patient’s tumor. The resulting cellular product is intended to present multiple cancer-associated signals to the immune system rather than relying on a single target.

“The vaccine trains the immune cells to recognize the cancer as if it were an infection,” said Justin Moser, M.D., the trial’s principal investigator and an associate clinical investigator in HonorHealth Research Institute’s Oncology Research Division. Moser, who specializes in melanoma, said conventional cancer vaccines have often produced immune responses that were not powerful or durable enough to control metastatic disease. The trial will test whether the personalized formulation can overcome some of those limitations in patients whose melanoma has resisted standard care.

The treatment’s design is based on the principle that tumors can evade immune surveillance by suppressing immune cells, altering the proteins displayed on their surfaces or creating a hostile environment around the cancer. By loading dendritic cells with both tumor-derived mRNA and proteins, researchers seek to provide the immune system with a broader set of instructions for identifying malignant cells. Joseph Georges, D.O., Ph.D., a neurosurgeon at Scottsdale Neurosurgery Specialists, said the dual-loading strategy generated an immune response nearly ten times greater than approaches using only mRNA or only protein materials in the research underlying the technology. That comparison reflects the developers’ findings and remains subject to clinical validation in melanoma patients.

The vaccine platform was previously investigated in a clinical trial for glioblastoma, the most common primary malignant brain tumor in adults. Georges contributed to preclinical studies supporting that work. According to HonorHealth, some participants in the early phases survived more than two or three years without significant adverse effects, exceeding the approximately 15-month average survival often cited for glioblastoma. Those observations helped prompt research into whether the same immune-training strategy could be adapted for other cancers, including melanoma and pancreatic cancer.

The dendritic-cell vaccine differs from tumor-infiltrating lymphocyte, or TIL, therapy, another cellular treatment available through HonorHealth Research Institute. TIL therapy removes naturally occurring immune cells from a patient’s tumor, expands and strengthens them in a laboratory, and then returns billions of these cells to the patient. Because TILs already possess some ability to recognize the tumor, the treatment seeks to amplify an existing response. DOC1021 takes a different route: it attempts to teach the immune system to recognize the cancer by using dendritic cells as biological messengers that activate and direct T cells and B cells.

TIL treatment commonly involves preparative chemotherapy and additional medicines to support the infused immune cells. DOC1021 is intended to activate the patient’s own immune system without those additional treatments, according to the researchers. That distinction could affect how the therapy is administered and which patients may be able to receive it, although the safety, effectiveness and durability of the vaccine response will need to be established through the trial. As with any investigational therapy, early laboratory or preliminary clinical findings cannot yet demonstrate that the treatment will extend survival or provide lasting tumor control.

The trial, titled “Dendritic Cell Immunotherapy for Refractory Melanoma,” is being conducted by HonorHealth Research Institute in collaboration with Diakonos Oncology, the Houston-based company developing DOC1021. Researchers will study the therapy in people with advanced melanoma that cannot be removed surgically or has spread to other organs after failing existing treatments. The research institute describes the study as a randomized controlled or clinical trial, but the announcement does not provide detailed information about the number of participants, treatment arms, eligibility criteria or primary endpoints. Those details will be important for interpreting the results as the study progresses.

The launch reflects a broader shift toward personalized immunotherapy, in which a patient’s tumor is used to generate treatment-specific molecular information. Cancer vaccines are intended not merely to stimulate immunity in general, but to focus immune cells on antigens that distinguish malignant tissue from healthy tissue. “Our immune system has the hardware to attack and kill cancer cells,” Georges said. “It’s just that cancers get really good at fooling our immune system.” By supplying immune cells with a more complete molecular portrait of a tumor, researchers hope to make that concealment more difficult. Whether DOC1021 can produce meaningful responses in treatment-resistant melanoma will depend on the outcomes of the ongoing clinical investigation.

Subject of Research: People

Article Title: Personalized Dendritic-Cell Vaccine Enters Clinical Trial for Treatment-Resistant Advanced Melanoma

News Publication Date: Aug. 11, 2026

Web References: www.honorhealthresearch.org

References: HonorHealth Research Institute; Diakonos Oncology; “Dendritic Cell Immunotherapy for Refractory Melanoma” clinical trial

Keywords: melanoma, advanced melanoma, cancer immunotherapy, dendritic cells, DOC1021, dubodencel, personalized cancer vaccine, mRNA, tumor proteins, clinical trial, metastatic cancer, refractory cancer, HonorHealth Research Institute

Central to this breakthrough is the role of conventional type I dendritic cells (cDC1s), a subset of antigen-presenting cells known for their potent ability to orchestrate adaptive immune responses. Unlike broad immunotherapeutic strategies that primarily amplify existing immune activity, this approach purposefully initiates a novel, tumor-specific immune response. By extracting dendritic cells from tumor-bearing mice, loading them ex vivo with tumor-derived antigens, and subsequently reintroducing them into the same host, researchers have uniquely managed to activate cytotoxic T lymphocytes capable of targeting primary tumors and thwarting future relapses.

Dendritic cells serve as sentinels within the immune system, able to capture, process, and present tumor-associated antigens to naive T cells, thereby igniting a cascade of immune activation. However, dendritic cells comprise a heterogeneous population, and prior to this study, the precise subset best suited to evoke long-lasting anti-cancer immunity remained elusive. The CNIC-led research conclusively identifies cDC1s as the optimal subset for generating a strong and durable immune memory response crucial to sustained tumor control.

Ignacio Heras-Murillo, the study’s first author and a researcher at CNIC, emphasizes the significance of this work by highlighting its departure from conventional immunotherapies. Whereas current treatments often act by enhancing pre-existing immune responses, this novel strategy “induces a new, highly specific immune response against the tumor,” addressing one of the major hurdles in oncology: preventing tumor relapse after initial remission.

The innovative treatment protocol involves isolating type I dendritic cells directly from mice afflicted with cancer. These cells are then pulsed in vitro with tumor antigens, a process that effectively “educates” the dendritic cells to recognize malignant cell markers. Upon reinjection into the host, these cells engage and activate T lymphocytes, which target tumor cells with precision. Notably, this results not only in immediate tumor regression but also in the establishment of immunological memory capable of intercepting any subsequent tumor growth.

Stefanie Wculek, co-supervisor of the study and currently at IRB Barcelona, elaborates on the clinical implications of these findings. The dual effect of the therapy — combining rapid tumor elimination with long-lasting immune vigilance — offers an encouraging framework for designing next-generation cancer immunotherapies capable of durable remission, a goal that has remained challenging for decades.

The study’s principal investigator, CNIC scientist David Sancho, underscores the ability of the cDC1-based immunotherapy to prevent tumor relapse by inducing immune memory. According to Sancho, this memory response effectively “prevents the growth of a second, similar tumor” in the mouse models, highlighting the potential to avert metastatic progression and improve overall survival outcomes.

While these preclinical findings mark a significant milestone, the researchers acknowledge that additional studies are required to translate the approach from mouse models to human patients. Key questions include the therapy’s effectiveness against metastatic disease, compatibility with existing treatments such as immune checkpoint inhibitors, and scalability for clinical use.

This research was conducted with generous support from numerous institutions, including the CNIC, Spain’s Ministerio de Ciencia, Innovación y Universidades, the Agencia Estatal de Investigación, the European Union’s NextGenerationEU/PRTR initiative, the Comunidad de Madrid, the “la Caixa” Foundation, the Fundación Científica de la Asociación Española Contra el Cáncer, and Worldwide Cancer Research.

The CNIC itself is a leading cardiovascular research center affiliated with the Carlos III Health Institute and funded through public-private partnerships. Directed by Dr. Valentín Fuster, the center is renowned for its dedication to translating scientific discoveries into practical medical solutions and has been recognized by the Spanish government as a Severo Ochoa Center of Excellence.

Published in the journal Nature Communications, this cutting-edge investigation represents a paradigm shift in cancer immunotherapy by leveraging the unique properties of conventional type I dendritic cells. The ability to induce a specific, lasting immune response that actively prevents tumor relapse opens the door to novel therapeutic regimes that may dramatically improve patient outcomes across diverse cancer types.

The precision of this dendritic cell-based strategy directly addresses the challenges of immune evasion and tumor recurrence, offering hope for durable remission where traditional therapies have often fallen short. As the understanding of dendritic cell biology deepens, the prospect of personalized immunotherapies tailored to the immune landscape of each patient becomes increasingly attainable.

Looking ahead, further exploration of combination regimens incorporating cDC1 immunotherapy with other modalities, such as chemotherapy, radiation, or immune checkpoint blockade, could yield synergistic effects and widen the scope of clinical applicability. This study lays the foundational knowledge essential for such translational efforts, marking an exciting step toward more effective and durable cancer treatments.

Ultimately, the successful harnessing of type I dendritic cells to induce immune memory represents a significant advancement in the quest for cancer therapies that not only extinguish primary tumors but also fundamentally alter the immune system’s capacity to protect against future malignancies. This work exemplifies the power of immunological innovation in defeating cancer and underscores the critical importance of continued investment in cutting-edge biomedical research.

—

Subject of Research: People

Article Title: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

News Publication Date: 9-Apr-2025

Web References:
– CNIC: https://www.cnic.es/en
– IRB Barcelona: https://www.irbbarcelona.org/es
– Nature Communications: https://www.nature.com/ncomms/
– DOI: http://dx.doi.org/10.1038/s41467-025-58289-1

Image Credits: CNIC

Keywords: Gene targeting, Primary tumors, Dendritic cells, Cancer immunotherapy, Immunological memory, Research organizations